This is a randomized, double-blind, placebo controlled multicenter study. A total of 700 patients will be included. After an updated powercalculation 560 was condidered enough The study will include patients with primary sclerosing cholangitis (PSC) for daily intake of 40 mg simvastatin/placebo for 5 years. The aim is to study effect of prognosis of PSC by long term intake of simvastatin. Outcome measures are death, liver transplantation, cholangiocarcinoma or bleeding from esophageal varices. Subjects will be randomized (1:1) between Simvastatin and placebo.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Overall survival
Timeframe: Time from the date of randomization to the date of death, assessed up to 5 years.
Listing for liver transplantation
Timeframe: Time from the date of randomization to the date of listing for liver transplantation, assessed up to 5 years.
Time to first varices bleeding
Timeframe: Time from the date of randomization to the date of the first varices bleeding, assessed up to 5 years.
Time to diagnosis of cholangiocarcinoma, gall bladder cancer, or hepatocellular cancer.
Timeframe: Time from the date of randomization to cancer diagnosis, assessed up to 5 years.